Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duvelisib - Verastem Oncology

Drug Profile

Duvelisib - Verastem Oncology

Alternative Names: ABBV-954; COPIKTRA; INK-1197; IPI-145

Latest Information Update: 02 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intellikine
  • Developer AbbVie; Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Verastem Oncology; Yakult Honsha
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Isoquinolines; Purines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Follicular lymphoma
  • Phase III Non-Hodgkin's lymphoma
  • Phase II Haematological malignancies; Peripheral T-cell lymphoma
  • Preclinical Solid tumours
  • No development reported Lymphoma; T-cell lymphoma
  • Discontinued Allergic asthma; Rheumatoid arthritis

Most Recent Events

  • 25 Nov 2019 Preregistration for Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater) in European Union (PO)
  • 25 Nov 2019 Preregistration for Follicular lymphoma (Combination therapy, Second-line therapy or greater) in European Union (PO)
  • 21 Nov 2019 Safety, efficacy, pharmacokinetics and pharmacodynamics data from the phase II PRIMO trial in Peripheral T-cell lymphoma released by Verastem Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top